Piper Sandler analyst Yasmeen Rahimi raised the firm’s price target on Prothena (PRTA) to $110 from $94 and keeps an Overweight rating on the shares. The firm notes Prothena has multiple key data readouts in 202. Piper remains bullish on Prothena and refreshed its model, increasing the AL amylolysis to $32/share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
- Prothena Reports 2024 Financial Results and 2025 Outlook
- Prothena’s Balanced Earnings Call Highlights Growth and Challenges
- Prothena price target lowered to $20 from $24 at RBC Capital
- Promising Potential of Birtamimab in Transforming AL Amyloidosis Treatment: Analyst Recommends Buy
- PRTA Upcoming Earnings Report: What to Expect?